Donaldson and PolyPeptide Partner to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology
May 13 2024 - 4:12PM
Business Wire
Companies’ combined ingenuity and desire for
sustainability unite to solve an industry challenge
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide
manufacturer of innovative filtration and separation products and
solutions, and PolyPeptide Group AG (SIX: PPGN), a global leader in
peptide manufacturing, today announced their collaboration on the
development of a production scale solvent recovery system for use
in peptide purification. Peptides are used as the active
pharmaceutical ingredient (API) in therapeutic areas, which
continue to broaden and include metabolic disorders, oncology,
infectious diseases, orphan diseases, cardiovascular, neurology or
gastro-enterology applications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240513059583/en/
The collaboration between Donaldson and PolyPeptide marks a
milestone in the pharmaceutical industry's pursuit of
environmentally friendly manufacturing practices. By leveraging
Donaldson's experience in filtration and separation technologies
and PolyPeptide’s expertise in peptide synthesis, the partnership
aims to introduce a pioneering solution for reclaiming and
purifying acetonitrile used in peptide purification. The technology
is intended to be utilized for the benefit of the entire peptide
manufacturing industry.
The patented, three-step solvent recovery technology was
deployed as a pilot system at Polypeptide’s manufacturing site in
Torrance, California. The system recovers chromatography solvent
and returns the acetonitrile to a level of purity that can be
reused in the peptide manufacturing process, which significantly
reduces solvent consumption and waste generation while maintaining
high product purity.
Current peptide manufacturing processes use large quantities of
solvents. These are often mixed with water in the peptide
purification process and are then disposed of through incineration,
posing environmental challenges. The introduction of this new,
advanced separation technology for acetonitrile used in
purification allows the water content in the solvent mixture to be
effectively removed, recovering the solvent for purification and
reuse.
“Donaldson is committed to solving complex filtration and
separation challenges to advance life- changing therapies and
supporting sustainable manufacturing practices,” said Andrew
Dahlgren, president Life Sciences. “We are excited to collaborate
with a global peptide leader like PolyPeptide on this solvent
recovery technology to support the industry’s sustainability
goals.”
“At PolyPeptide, we collaborate with our customers in the early
product development phase to apply relevant principles of green
chemistry,” said Brad Grossman, head of production for PolyPeptide
in Torrance. “Our partnership with Donaldson is part of our
comprehensive innovation efforts to reduce, recycle, replace, or
even avoid hazardous solvents used in production.”
About Donaldson Company,
Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in
technology-led filtration products and solutions, serving a broad
range of industries and advanced markets. Diverse, skilled
employees at over 140 locations on six continents partner with
customers – from small business owners to R&D organizations and
the world’s biggest OEM brands. Donaldson solves complex filtration
challenges through three primary segments: Mobile Solutions,
Industrial Solutions and Life Sciences. Additional information is
available at Donaldson.com.
About PolyPeptide
PolyPeptide Group AG with its consolidated subsidiaries
(“PolyPeptide”) is a focused Contract Development &
Manufacturing Organization (CDMO) which specializes in the
development and manufacturing of synthetic peptides and
oligonucleotides used as active pharmaceutical ingredients (API) or
intermediates in therapeutic products. It also produces a range of
generic peptides and peptides used in cosmetics. The Group mainly
serves pharmaceutical and biotech companies. By supporting its
customers, PolyPeptide contributes to the health of millions of
patients across the world. Established in 1952, PolyPeptide today
runs a global network of six GMP-certified facilities in Europe,
the U.S. and India. Additional information is available at
Polypeptide.com.
Disclaimer
This media release has been prepared by Donaldson Company, Inc.,
and PolyPeptide Group AG and contains certain forward-looking
statements that reflect the current views of management. Such
statements are subject to known and unknown risks, uncertainties
and other factors that may cause actual developments to differ
materially from those expressed or implied in this release.
Donaldson Company, Inc. and PolyPeptide Group AG are providing the
information in this release as of this date and, except as required
by applicable laws or regulations, do not undertake any obligation
to update any statements contained in it as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513059583/en/
Donaldson: Sarika Dhadwal, sarika.dhadwal@donaldson.com
PolyPeptide: Michael Stäheli, michael.staeheli@polypeptide.com
Donaldson (NYSE:DCI)
Historical Stock Chart
From Apr 2024 to May 2024
Donaldson (NYSE:DCI)
Historical Stock Chart
From May 2023 to May 2024